In this episode of Bladder Cancer Matters, host Rick Bangs speaks with Dr. Josefa Briceno of AstraZeneca about why bladder cancer care may be at a true turning point. From exploring immunotherapy earlier in the disease journey — even around the time of surgery — to strengthening collaboration between urologists and medical oncologists, the conversation highlights how timing, teamwork, and informed shared decision-making are reshaping care.

Dr. Briceno explains what this shift means for patients, why education and self-advocacy are essential, and how partnerships between industry and advocacy organizations like BCAN help ensure innovation reflects real patient needs.

It's a hopeful, forward-looking discussion about where bladder cancer treatment is headed — and why patients should feel empowered to be active participants in their care.